FGP
CMPX icon

Freestone Grove Partners’s Compass Therapeutics CMPX Stock Holding History

Freestone Grove Partners’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2 Buy
+1
New +$3 ﹤0.01% 986

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Freestone Grove Partners's CMPX Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Compass Therapeutics (CMPX) in Q2 2026: 1 share worth $2. The stake represents ﹤0.01% of the portfolio and ranks #986 among its holdings.

215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Freestone Grove Partners held 1 share of Compass Therapeutics worth $2 as of Q2 2026.
  • Compass Therapeutics was a new Freestone Grove Partners position in Q2 2026.
  • Compass Therapeutics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #986 holding.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.